Therefore, differential induction of anti-apoptotic genes directly by NF-kB and pro-apoptotic genes through NF-kB target IRF1, may determine ER+ breast tumor predisposition to succumb or resist endocrine therapy. The gene discussed is NFKB1; the disease is breast neoplasm.